A Research Study Examining the Use of Olanzapine for the Prevention of Migraine

Exclusion Criteria

• •Women who are pregnant or lactating
• •Subjects with an abnormal ECG that, in the investigators opinion, would expose them to increased risk of adverse events or interfere with study drug and/or analysis of efficacy/tolerability (subjects with QTC interval greater than 450ms will be excluded)
• •Subjects currently taking, or have taken within the thirty days prior to screening, any neuroleptics \> 1 day per week (such as Geodon, Zyprexa, Compazine, Phenergan, Seroquel and other drugs in the same class)
• •Subjects currently taking or have taken within 4-weeks prior to screening any medication for the prevention of migraine
• •Subjects who have failed more than two adequate trials of migraine prophylaxis, as determined by investigator
• •Subjects who experience significant orthostatic hypotension, as determined by the investigator
• •Subjects who, in the investigators opinion, have a history or have evidence of a medical condition that would expose them to an increased risk of a significant adverse event or would interfere with the assessments of efficacy and tolerability during this trial
• •Subjects who, in the investigators opinion, have a history or have evidence of a psychiatric condition that would expose them to an increased risk of a significant adverse event or would interfere with the assessments of efficacy and tolerability during this trial.
• •Subjects who have participated in an investigational drug trial in the 30 days prior to the screening visit